Navidea Biopharmaceuticals Inc (NAVB)

[cricket69]

Analysis: Positioning to Benefit within Foamix Pharmaceuticals, Era Group, Orion Group, Intermolecular, Navidea Biopharmaceuticals, and Evelo Biosciences -- Research Highlights Growth, Revenue, and Consolidated Results

8:55 am ET April 17, 2019 (Globe Newswire) Print


In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), Era Group, Inc. (NYSE:ERA), Orion Group Holdings, Inc. (NYSE:ORN), Intermolecular, Inc. (NASDAQ:IMI), Navidea Biopharmaceuticals, Inc. (NYSE:NAVB), and Evelo Biosciences, Inc. (NASDAQ:EVLO), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

FOMX DOWNLOAD: http://Capital-Review.com/register/?so=FOMX

ERA DOWNLOAD: http://Capital-Review.com/register/?so=ERA

ORN DOWNLOAD: http://Capital-Review.com/register/?so=ORN

IMI DOWNLOAD: http://Capital-Review.com/register/?so=IMI

NAVB DOWNLOAD: http://Capital-Review.com/register/?so=NAVB

EVLO DOWNLOAD: http://Capital-Review.com/register/?so=EVLO

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Capital Review, available for free download at the links above, examine Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), Era Group, Inc. (NYSE:ERA), Orion Group Holdings, Inc. (NYSE:ORN), Intermolecular, Inc. (NASDAQ:IMI), Navidea Biopharmaceuticals, Inc. (NYSE:NAVB), and Evelo Biosciences, Inc. (NASDAQ:EVLO) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

FOAMIX PHARMACEUTICALS LTD. (FOMX) REPORT OVERVIEW

Foamix Pharmaceuticals' Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Foamix Pharmaceuticals reported revenue of $0.86MM vs $1.04MM (down 17.55%) and analysts estimated basic earnings per share -$0.17 vs -$0.46. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Foamix Pharmaceuticals reported revenue of $3.60MM vs $3.67MM (down 2.02%) and analysts estimated basic earnings per share -$1.70 vs -$1.76. Analysts expect earnings to be released on May 14th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$0.69. The estimated EPS forecast for the next fiscal year is -$1.32 and is expected to report on February 27th, 2020.

To read the full Foamix Pharmaceuticals Ltd. (FOMX) report, download it here: http://Capital-Review.com/register/?so=FOMX

-----------------------------------------

ERA GROUP, INC. (ERA) REPORT OVERVIEW

Era Group's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Era Group reported revenue of $52.02MM vs $57.53MM (down 9.59%) and analysts estimated basic earnings per share -$0.25 vs $2.95. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Era Group reported revenue of $221.68MM vs $231.32MM (down 4.17%) and analysts estimated basic earnings per share $0.64 vs -$1.36. Analysts expect earnings to be released on May 7th, 2019. The report will be for the fiscal period ending March 31st, 2019.

To read the full Era Group, Inc. (ERA) report, download it here: http://Capital-Review.com/register/?so=ERA

-----------------------------------------

ORION GROUP HOLDINGS, INC. (ORN) REPORT OVERVIEW

Orion Group's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Orion Group reported revenue of $99.21MM vs $162.21MM (down 38.84%) and analysts estimated basic earnings per share -$3.32 vs $0.34. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Orion Group reported revenue of $520.89MM vs $578.55MM (down 9.97%) and analysts estimated basic earnings per share -$3.31 vs $0.01. Analysts expect earnings to be released on May 2nd, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was -$0.01. The estimated EPS forecast for the next fiscal year is $0.14 and is expected to report on March 24th, 2020.

To read the full Orion Group Holdings, Inc. (ORN) report, download it here: http://Capital-Review.com/register/?so=ORN

-----------------------------------------

INTERMOLECULAR, INC. (IMI) REPORT OVERVIEW

Intermolecular's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Intermolecular reported revenue of $6.32MM vs $10.55MM (down 40.07%) and basic earnings per share -$0.06 vs $0.01. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Intermolecular reported revenue of $33.66MM vs $37.20MM (down 9.52%) and analysts estimated basic earnings per share -$0.07 vs -$0.21. Analysts expect earnings to be released on May 14th, 2019. The report will be for the fiscal period ending March 31st, 2019.

To read the full Intermolecular, Inc. (IMI) report, download it here: http://Capital-Review.com/register/?so=IMI

-----------------------------------------

NAVIDEA BIOPHARMACEUTICALS, INC. (NAVB) REPORT OVERVIEW

Navidea Biopharmaceuticals' Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Navidea Biopharmaceuticals reported revenue of $0.12MM vs $0.40MM (down 69.81%) and analysts estimated basic earnings per share -$0.01 vs -$0.02. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Navidea Biopharmaceuticals reported revenue of $1.17MM vs $1.81MM (down 35.41%) and analysts estimated basic earnings per share -$0.09 vs $0.47. Analysts expect earnings to be released on May 14th, 2019. The report will be for the fiscal period ending March 31st, 2019.

To read the full Navidea Biopharmaceuticals, Inc. (NAVB) report, download it here: http://Capital-Review.com/register/?so=NAVB

-----------------------------------------